Department of Orthopaedic Surgery, National Center for Geriatrics and Gerontology, 35 Gengo, Obu, Aichi, Japan.
Department of Hematology, National Center for Geriatrics and Gerontology, Obu, Aichi, Japan.
J Bone Miner Metab. 2021 Nov;39(6):1048-1057. doi: 10.1007/s00774-021-01242-1. Epub 2021 Jul 1.
Red blood cell distribution width (RDW) has been evaluated as a potential screening marker for cancer and prognostic marker in heart failure and coronary heart disease. Recent studies have been suggested the association of RDW with mortality in patients with hip fracture and arthroplasty. Objective of this study was to investigate whether RDW as a prognostic marker is significant in patients with osteoporotic vertebral fracture (OVF).
Total of 460 patients with fresh OVF from January 2014 and September 2017 were assessed for a 1-year follow-up period. The cutoff value for RDW was set at 15%, and outcomes of conservative treatment of OVF were evaluated using the Japanese Orthopaedic Association (JOA) scores, Barthel index, and walking state.
Of the total 460 patients, 125 patients (27.2%) had an elevated RDW. RDW value was not correlated with osteoporotic parameters. Both JOA score and Barthel index were significantly lower at 1 year after treatment in the elevated RDW group. In the elevated RDW group, 21 patients died within 1 year (mortality 16.8%) compared with 7 patients (mortality 2.1%) in the non-elevated RDW group; this was statistically significant. Multivariate statistical analysis showed elevated RDW, independent walk before OVF and skeletal muscle mass index (SMI) remained independent factors associated with abasia after OVF affected.
Elevated RDW was associated with the poor clinical outcomes of conservative treatment of an OVF, independent of osteoporosis or severity of the OVF. RDW provides prognostic information for risk stratification as a senescence biomarker.
红细胞分布宽度(RDW)已被评估为癌症的潜在筛查标志物以及心力衰竭和冠心病的预后标志物。最近的研究表明,RDW 与髋部骨折和关节置换患者的死亡率相关。本研究旨在探讨 RDW 作为预后标志物在骨质疏松性椎体骨折(OVF)患者中的意义。
评估了 2014 年 1 月至 2017 年 9 月期间的 460 例新鲜 OVF 患者,随访 1 年。将 RDW 的临界值设定为 15%,并使用日本矫形协会(JOA)评分、Barthel 指数和行走状态评估 OVF 保守治疗的结果。
在总共 460 例患者中,125 例(27.2%)RDW 升高。RDW 值与骨质疏松参数无关。在治疗后 1 年,升高的 RDW 组的 JOA 评分和 Barthel 指数均显著降低。在升高的 RDW 组中,21 例患者在 1 年内死亡(死亡率为 16.8%),而非升高的 RDW 组中仅 7 例患者死亡(死亡率为 2.1%);差异有统计学意义。多变量统计分析表明,升高的 RDW、OVF 前独立行走和骨骼肌质量指数(SMI)仍然是影响 OVF 后步行障碍的独立因素。
升高的 RDW 与 OVF 保守治疗的不良临床结果相关,与骨质疏松症或 OVF 的严重程度无关。RDW 作为衰老生物标志物提供预后信息以进行风险分层。